Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Sirna-027
AGN211745 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Single intravitreal injection |
| 2 | EXPERIMENTAL | Single intravitreal injection |
| 3 | EXPERIMENTAL | Single intravitreal injection |
| 4 | EXPERIMENTAL | Single intravitreal injection |
| 5 | EXPERIMENTAL | Single intravitreal injection |
| 6 | EXPERIMENTAL | Single intravitreal injection |
| Name | Type | Description |
|---|---|---|
| AGN211745 | DRUG | 100microgram single intravitreal injection |
Inclusion Criteria: * Active AMD with Subfoveal CNV (classic and/or occult CNV) * CNV lesion thickness \>/= 250um by OCT assessment * Visual acuity in study eye of \</= 20/100 but not worse than 20/800 * Not eligible for or refused standard treatment Exclusion Criteria: * Females of childbearing ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
AGN211745 is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) for age-related macular degeneration. It is an RNA interference inhibitor that targets FLT1. It was studied as an intravitreal injection in patients with subfoveal choroidal neovascularization secondary to AMD.
AGN211745 was studied for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. The single clinical trial enrolled patients aged 50 years and older with this condition. It was administered as an intravitreal injection. The program is in Phase 1 development and is not approved for any use.
AGN211745 targets FLT1, also known as vascular endothelial growth factor receptor 1. It is classified as an RNA interference inhibitor, a small molecule designed to interfere with FLT1 expression. Targeting FLT1 is intended to address the abnormal blood vessel growth seen in age-related macular degeneration.
AGN211745 is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the sponsor associated with the drug's clinical development program in ophthalmology. The asset was studied for age-related macular degeneration and related choroidal neovascularization.
AGN211745 is in Phase 1 development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active. The completed study enrolled 26 patients.
AGN211745 was evaluated in one completed Phase 1 trial, NCT00363714, titled a dose escalation trial of an intravitreal injection of Sirna-027 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The trial enrolled 26 patients in the United States, included a control group, and was not randomized or double blinded.